Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >/= 50. J Clin Oncol 2021 Apr 19:JCO2100174. doi: 10.1200/JCO.21.00174.
PMID: 33872070